This news release constitutes a "designated news release" for the purposes of the Company's amended and restated prospectus supplement dated November 18, 2025, to its short form base shelf prospectus dated May 15, 2025. MIAMI, FL / ACCESS Newswire / February 20, 2026 / DigiPower X Inc. ("Digipower X" or the "Company") (Nasdaq:DGXX)(TSXV:DGX), a vertically integrated AI infrastructure company focused on the deployment of Tier-3 modular data centers powered by owned and controlled energy assets, announces tha ...

Secaucus, New Jersey-based Quest Diagnostics Incorporated (DGX) provides diagnostic testing and services in the United States and internationally. Valued at a market capitalization of $23 billion, the company develops and delivers diagnostic information services, including routine, non-routine, and advanced clinical testing, anatomic pathology testing, and other diagnostic services. The company's shares have outperformed the broader market over the past year and in 2026. DGX stock has surged 21.8% over t ...

Company Performance - Quest Diagnostics (DGX) shares have increased by 14.1% over the past month, reaching a new 52-week high of $207.05 [1] - The stock has gained 18.3% since the beginning of the year, outperforming the Zacks Medical sector's 0.9% gain and the Zacks Medical - Outpatient and Home Healthcare industry's 9.7% return [1] Earnings and Valuation - The company has a strong record of positive earnings surprises, beating the Zacks Consensus Estimate in the last four quarters [2] - In the latest earnings report on February 10, 2026, Quest Diagnostics reported EPS of $2.42, exceeding the consensus estimate of $2.35, and beat the revenue estimate by 2.08% [2] - The stock currently trades at 19.7X current fiscal year EPS estimates, which is a premium compared to the peer industry average of 18.9X [6] - On a trailing cash flow basis, the stock trades at 13.5X versus the peer group's average of 18.8X, with a PEG ratio of 2.59 [6] Zacks Rank and Style Scores - Quest Diagnostics holds a Zacks Rank of 2 (Buy) due to favorable earnings estimate revisions from analysts [7] - The company has a Value Score of B, Growth Score of B, and Momentum Score of B, resulting in a combined VGM Score of A [5][8] Industry Comparison - DaVita Inc. (DVA) is a notable peer with a Zacks Rank of 1 (Strong Buy) and a Value Score of A, indicating strong performance in comparison [9] - DaVita Inc. reported earnings that beat consensus estimates by 4.94%, with expected earnings of $14.16 per share on revenue of $14.11 billion for the current fiscal year [10] - Despite the Medical - Outpatient and Home Healthcare industry ranking in the bottom 59% of all industries, there are positive tailwinds for both DGX and DVA [11]

Core Viewpoint - Quest Diagnostics has received a stock upgrade to "Buy" from Jefferies, reflecting confidence in its financial health and growth prospects, with a price target increase from $215 to $220 [1][6] Financial Performance - In Q4 2025, Quest Diagnostics reported revenues of $2.81 billion, a 7.1% increase from the previous year, with diluted EPS rising by 11.8% to $2.18 and adjusted EPS at $2.42 [2] - For the full year 2025, the company achieved revenues of $11.04 billion, an 11.8% increase from 2024, with diluted EPS at $8.75 (up 13.8%) and adjusted EPS at $9.85 (up 10.3%) [3] Future Projections - Quest Diagnostics projects 2026 revenues between $11.70 billion and $11.82 billion, with expected diluted EPS between $9.45 and $9.65, and adjusted EPS ranging from $10.50 to $10.70, supported by strategic focus on clinical innovations [4] Shareholder Returns - The company announced a 7.5% increase in its quarterly dividend to $0.86 per share, marking the 15th consecutive year of dividend increases, and authorized a $1 billion increase in its share repurchase program [5][6]

Core Insights - Quest Diagnostics Inc. reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.42, exceeding the Zacks Consensus Estimate by 2.85% and up 8.5% year-over-year [1][2] - The company’s full-year 2025 adjusted EPS was $9.85, reflecting a 10.3% increase from the previous year and surpassing the Zacks Consensus Estimate by 0.5% [2] Revenue Performance - Fourth-quarter revenues increased by 7.1% year-over-year to $2.81 billion, beating the Zacks Consensus Estimate by 2.08% [3][4] - Diagnostic Information Services revenues rose 7.3% year-over-year to $2.74 billion, with requisition volumes up 8.5% [3][7] Margin Analysis - The cost of services for the quarter was $1.90 billion, a 7.5% increase year-over-year, while gross profit was $910 million, up 6.1% [5] - The gross margin decreased by 30 basis points to 32.4%, and the adjusted operating margin contracted by 49 basis points to 14.5% [5][10] Financial Position - At the end of the fourth quarter of 2025, cash and cash equivalents were $420 million, down from $549 million at the end of 2024 [6] - Cumulative net cash from operating activities was $1.89 billion, an increase from $1.33 billion at the end of 2024 [6] 2026 Guidance - For full-year 2026, revenues are projected to be between $11.70 billion and $11.82 billion, indicating a year-over-year growth of 6% to 7.1% [7][8] - Adjusted EPS is expected to be in the range of $10.50 to $10.70, with the Zacks Consensus Estimate at $10.45 [8] Strategic Execution - The company has focused on deploying AI and automation across its systems and has introduced innovations in its Advanced Diagnostics portfolio [10] - Quest Diagnostics achieved 3% annual cost savings and productivity improvements through its Invigorate program [10]

Financial Data and Key Metrics Changes - In Q4 2025, consolidated revenues reached $2.81 billion, reflecting a 7.1% increase year-over-year. Organic revenues grew by 6.4% [15] - Reported operating income was $386 million, maintaining a margin of 13.8%, while adjusted operating income was $429 million, or 15.3% of revenues, compared to 15.6% the previous year [16] - Reported EPS was $2.18, and adjusted EPS was $2.42, up from $1.95 and $2.23 respectively in the prior year [16] Business Line Data and Key Metrics Changes - Diagnostic information services revenues increased by 7.3%, driven by organic growth across physician, hospital, and consumer channels [15] - In the physician channel, organic revenue growth was high single digits, while hospital channel revenues grew low single digits [9] - The consumer channel generated nearly $250 million in revenues for the full year, with growth exceeding 20% [11] Market Data and Key Metrics Changes - Total volume measured by requisitions increased by 8.5%, with organic volume up 7.9% [15] - Excluding significant volume growth from Corewell Health and Fresenius Medical Care, organic volume growth was 4.1% [15] - The company expects to generate approximately $1 billion in annual revenues from co-lab solutions in 2026 [10] Company Strategy and Development Direction - The company aims to expand its clinical innovations and strategic collaborations to enhance its position in the wellness industry [5] - Focus areas include advanced diagnostics in cardiometabolic, autoimmune, brain health, oncology, and women's health [12] - The company is pursuing acquisitions and partnerships to enhance its service offerings and market reach [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in business strengths and market fundamentals, citing favorable demographic trends and increasing demand for blood-based diagnostics [5] - The delay in PAMA implementation until the end of 2026 was viewed as a positive development, providing short-term relief [6] - The company anticipates continued organic growth driven by innovations and strategic partnerships [21] Other Important Information - The company achieved a significant increase in cash from operations, totaling $1.89 billion for the full year, compared to $1.33 billion in the prior year [17] - Capital expenditures for 2026 are expected to be approximately $550 million [17] Q&A Session Summary Question: What are the underlying growth drivers for 2026? - Management highlighted strong organic growth in Alzheimer's testing, autoimmune testing, and partnerships with wellness companies as key drivers [24][26] Question: How is the company addressing the impact of severe weather on Q1? - Management noted strong growth in early January but acknowledged the impact of severe storms, expressing confidence in recovery throughout the quarter [27][29] Question: Can you discuss the moving pieces on margins for 2026? - Management indicated that operating margins are expected to increase, despite the impact of lower-margin co-lab business from Corewell [37][39] Question: What is the competitive landscape like for the company? - Management emphasized share gains in organic growth and the strength of their national coverage as competitive advantages [45][46] Question: How is the company planning to monetize its data? - Management discussed the growth of the data business, highlighting its value to pharmaceutical companies and payers [90]

Financial Data and Key Metrics Changes - In Q4 2025, consolidated revenues reached $2.81 billion, reflecting a 7.1% increase year-over-year, with organic revenues growing by 6.4% [15][16] - Reported operating income was $386 million, maintaining a margin of 13.8%, while adjusted operating income was $429 million, or 15.3% of revenues, compared to 15.6% the previous year [16] - Reported EPS was $2.18, and adjusted EPS was $2.42, up from $1.95 and $2.23 respectively in the prior year [16] Business Line Data and Key Metrics Changes - In the physician channel, organic revenue growth was high single digits, driven by demand for advanced diagnostics and geographic expansion [9] - Hospital channel revenues grew low single digits, with collaborative lab solutions contributing to growth [9] - The consumer channel generated nearly $250 million in revenues for the full year, exceeding the expected growth rate of over 20% [11] Market Data and Key Metrics Changes - Total volume measured by requisitions increased by 8.5% year-over-year, with organic volume up 7.9% [15] - Excluding significant relationships with Corewell Health and Fresenius Medical Care, organic volume growth was 4.1% [15] - The company expects to generate approximately $1 billion in annual revenues from co-lab solutions in 2026 [10] Company Strategy and Development Direction - The company aims to expand its clinical innovations and strategic collaborations to enhance its position in the wellness industry [5] - Focus on delivering solutions for core clinical customers while also targeting growth in consumer, life sciences, and data analytics [8] - The company is pursuing potential acquisitions and partnerships to enhance its service offerings and market reach [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in business strengths and market fundamentals, citing favorable demographic trends and increasing demand for blood-based diagnostics [5] - The delay in PAMA implementation until the end of 2026 was viewed as a positive development, providing short-term relief [6][7] - Management anticipates continued strong organic growth driven by advancements in testing and strategic partnerships [24] Other Important Information - The company achieved its target of 3% annual cost savings and productivity improvements in 2025 through operational excellence initiatives [14] - Cash from operations for the full year was $1.89 billion, significantly up from $1.33 billion in the prior year [17] - The company expects capital expenditures of approximately $550 million in 2026 [18] Q&A Session Summary Question: What are the underlying growth drivers for 2026? - Management highlighted strong organic growth in Alzheimer's testing, autoimmune testing, and partnerships with wellness companies as key drivers [24][26] Question: How is the company addressing the impact of severe weather on operations? - Management noted strong growth in early January but acknowledged that severe weather affected operations later in the month, with confidence in recovery [27][29] Question: Can you discuss the moving pieces on margins for 2026? - Management indicated that operating margins are expected to increase, despite the impact of low-margin co-lab business and Project Nova expenses [37][39] Question: What is the competitive landscape like for the company? - Management emphasized share gains in organic growth and the strength of national coverage as competitive advantages [45][46] Question: How is the company planning to monetize its data? - Management discussed the growth of the data business, targeting pharmaceutical companies and payers as key customers [90]

Financial Data and Key Metrics Changes - In Q4 2025, consolidated revenues reached $2.81 billion, reflecting a 7.1% increase year-over-year. Consolidated organic revenues grew by 6.4% [14] - Reported operating income was $386 million, maintaining a margin of 13.8%, while adjusted operating income was $429 million, or 15.3% of revenues, compared to 15.6% the previous year [15] - Reported EPS was $2.18, and adjusted EPS was $2.42, compared to $1.95 and $2.23 in the prior year, respectively [15] Business Line Data and Key Metrics Changes - In the physician channel, organic revenue growth was high single digits in Q4, driven by demand for advanced diagnostics and geographic expansion [7] - Hospital channel revenues grew low single digits, with collaborative lab solutions contributing to growth [8] - The consumer channel generated nearly $250 million in revenues for the full year, with consumer-initiated testing exceeding 20% growth [10] Market Data and Key Metrics Changes - Total volume measured by requisitions increased by 8.5% year-over-year, with organic volume up 7.9% [14] - Excluding significant volume growth from Corewell Health and Fresenius Medical Care, organic volume growth was 4.1% in Q4 [14][51] Company Strategy and Development Direction - The company aims to enhance its position as a premier lab engine in the wellness industry, focusing on clinical innovations and strategic collaborations [4] - The delay in PAMA implementation until the end of 2026 is seen as a short-term relief, but the company advocates for structural reforms to prevent excessive rate cuts [5][6] - The company is pursuing acquisitions and partnerships to expand its co-lab solutions and consumer testing capabilities [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in business strengths and market fundamentals, including favorable demographic trends and increasing interest in preventative health [4] - The company anticipates a revenue growth rate of 6%-7.1% for 2026, with adjusted EPS expected to be in the range of $10.50-$10.70 [16][17] - Management acknowledged challenges from severe weather impacting early 2026 but remains optimistic about recovery [25][28] Other Important Information - The company achieved its target of 3% annual cost savings and productivity improvements in 2025 through operational excellence initiatives [13] - The consumer testing segment is expected to continue growing, supported by partnerships with wellness companies and a strong focus on preventative health [60][66] Q&A Session Summary Question: What are the underlying growth drivers for 2026? - Management highlighted strong organic growth in Alzheimer's testing, autoimmune testing, and partnerships with wellness companies as key drivers [23][24] Question: How is the company addressing the impact of severe weather on growth? - Management noted that while January faced challenges, they expect recovery in the remaining quarters and have systems in place to track and reschedule missed appointments [25][28] Question: Can you discuss the moving pieces on margins for 2026? - Management indicated that operating margins are expected to increase, despite the impact of low-margin co-lab business from Corewell and Project Nova expenses [35][39] Question: What is the competitive environment like for the company? - Management emphasized that the company is gaining market share, particularly in key states, and highlighted its national coverage as a competitive strength [44][46] Question: How is the company planning to monetize its data? - Management discussed the growth of its data business, which serves pharmaceutical companies, payers, and public health agencies, and mentioned partnerships with AI companies to enhance data utilization [84][86]

Core Viewpoint - Quest Diagnostics reported quarterly earnings of $2.42 per share, exceeding the Zacks Consensus Estimate of $2.35 per share, and showing an increase from $2.23 per share a year ago, representing an earnings surprise of +2.85% [1] Financial Performance - The company achieved revenues of $2.81 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.08%, compared to $2.62 billion in the same quarter last year [2] - Over the last four quarters, Quest Diagnostics has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance - Quest Diagnostics shares have increased approximately 10.2% since the beginning of the year, outperforming the S&P 500's gain of 1.7% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.37 on revenues of $2.75 billion, and for the current fiscal year, it is $10.45 on revenues of $11.35 billion [7] - The trend of estimate revisions for Quest Diagnostics was favorable ahead of the earnings release, which may influence future stock movements [5][6] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which Quest Diagnostics belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, indicating potential challenges in overall industry performance [8]

Q4 2025 Performance A strong fourth quarter to finish 2025 Read our Q4 earnings press release on our Investor Relations site. " We closed 2025 with a strong fourth quarter and delivered double-digit growth in revenues and earnings per share for the full year. Our robust performance demonstrates continued execution of our strategy to deliver category-defining clinical innovations that fulfill customers' needs and to form strategic collaborations supporting growth. Our 2026 guidance reflects our continued con ...